Prolatan, eye drops 0.005% 2.5ml

Latanoprost, an analogue of prostaglandin F2 alpha, is a selective FP receptor agonist and reduces intraocular pressure (IOP) by increasing aqueous outflow, mainly by uveoscleral route, as well as through the trabecular meshwork. IOP lowering starts approximately 3 – 4 hours after the drug injection, the maximum effect is observed after 8 – 12 hours and the action lasts for at least 24 hours.

It is established that latanoprost has no significant effect on aqueous humor production and on hemato-ophthalmic barrier.

When used in therapeutic doses latanoprost has no significant pharmacological effect on cardiovascular and respiratory systems.

Indications

Increased intraocular pressure, GlaucomaReducing elevated intraocular pressure (IOP) in adults and children (over 1 year of age) with open-angle glaucoma or increased ophthalmotonus.

Note: In children younger than 3 years with primary congenital glaucoma, surgical treatment (trabeculotomy/goniotomy) remains the first-line therapy.

Active ingredient

Latanoprost

Composition

1 ml contains:

The active ingredients:

latanoprost – 0.05 mg,

Excipients:

benzalkonium chloride – 0.2 mg,

sodium chloride – 4.1 mg,

dinatrium hydrophosphate anhydrous – 4.74 mg,

sodium dihydrophosphate monohydrate – 4.6 mg,

d/i water – up to 1 ml.

How to take, the dosage

For adult patients and children after 1 year of age, the standard dosage is one drop of Prolatan solution once daily into the affected eye conjunctivally.
Optimal effect is achieved if the drug is applied in the evening.

If a dose is missed, the next dose is administered at the usual time.

Interaction

A paradoxical increase in IOP has been described when two prostaglandin analogues are simultaneously injected into the eye, so the simultaneous use of two or more prostaglandins, their analogues or derivatives is not recommended.

Pharmaceutically incompatible with eye drops containing thiomersal – precipitation.

Contraindications

Hypersensitivity to latanoprost or other components of the drug. Age under 1 year (efficacy and safety have not been established).

With caution

Aphakia, pseudoaphakia with rupture of the posterior lens capsule, patients with known risk factors for macular edema (cases of macular edema, including cystoid edema, have been described during treatment with latanoprost); inflammatory, neovascular or congenital glaucoma (due to insufficient experience with the drug); asthma; history of herpetic keratitis.

Prolatan® should be avoided in patients with an active form of herpetic keratitis and recurrent herpetic keratitis, especially associated with the intake of prostaglandin analogues. Prolatan® should be used with caution in patients with risk factors for iritis/veitis.

There are limited data on the use of Prolatan® in patients scheduled for cataract surgery. In this regard, Prolatan® should be used with caution in this group of patients.

Side effects

• increase in the number, length and thickness of eyelash hairs, darkening of eyelid skin, change in iris color, iritis, uveitis, macular edema.
• Blurred vision, eye discomfort, conjunctival redness, pitting epithelial keratopathy, eyelid edema, eyelid crusts, photophobia, conjunctivitis, diplopia.Retinal detachment, vitreous hemorrhages in diabetic retinopathy…
• Respiratory tract infections, angina pectoris, muscle pain, heart rhythm disorders.
• Allergic reactions, rash..
• Bronchial asthma, bronchospasm, shortness of breath.

.

Overdose

Overdose with Prolatan solution is characterized by reddening of the conjunctiva and episclera, nausea, abdominal pain, sweating, hot flashes, fatigue, dizziness.

Symptomatic therapy should be administered if necessary.

Similarities

Xalatan, Xalatamax, Glauprost, Glaumax, Prolatan, Trilactan, Latanoprost-Optic